flow trial semaglutide kidney outcomes 2024 nejm hazard ratio 🔴Cardiovascular with by severity of chronic disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants 🚨 Journal Club: FLOW Trial

To address this question, we performed an integrated time-resolved analysis of the renal transcriptome and proteome in parallel with the renal and plasma metabolomes in control mice and mice with an induced deletion of Bmal1 in the renal tubule

Physiology-Cell Physiology 314, C662C674

The enlarged hair follicles produce the stem cells needed to rebuild skin

The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in non-diabetic patients with obesity and established cardiovascular disease

PepsiCo CEO Ramon Laguarta mentioned the GLP-1 trend at the company's earnings announcement in February, saying he would expand smaller-portion products and pursue the development of products fortified with protein and dietary fiber

This means you wait at least 4 hours between your daily meals, and 12 hours between dinner and breakfast the next day